Internal Medicine, Hematology & Oncology · White Plains, NY
NPI
1528225695
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
210 Westchester Ave
White Plains, NY, 10604
Phone (914) 681-5200
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.4M
340,618 services
Medicare patients, 2024
628
Average age 77
Drug cost, 2024
$6.7M
2,009 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew S Weissler was code J1439 (injection, ferric carboxymaltose, 1 mg), 86,250 times for 57 patients. In total Matthew S Weissler billed 340,618 services in 171 codes, and Medicare paid $4.4M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-11-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 86,250 | 57 | $0.87 | $75K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 21,800 | 11 | $44.83 | $977K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 20,600 | 12 | $0.06 | $1,145 |
| J1453 Injection, fosaprepitant, 1 mg | Office | 13,650 | 20 | $0.11 | $1,527 |
| J1756 Injection, iron sucrose, 1 mg | Office | 8,800 | 21 | $0.16 | $1,393 |
| J0897 Injection, denosumab, 1 mg | Office | 8,340 | 24 | $20.82 | $174K |
| Q5107 Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 5,669 | 12 | $20.72 | $117K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,368 | 43 | $0.09 | $394 |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 3,460 | 16 | $5.67 | $20K |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 2,484 | 15 | $3.56 | $8,854 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 2,252 | 21 | $0.07 | $167 |
| J9190 Injection, fluorouracil, 500 mg | Office | 1,681 | 18 | $2.32 | $3,890 |
| 99214 Office E&M - Established | Office | 1,674 | 450 | $108.39 | $181K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 1,250 | 26 | $0.69 | $864 |
| 36415 Venipuncture Blood Collection | Office | 1,160 | 408 | $8.64 | $10K |
By year: 2022 $4.5M for 362,633 services; 2023 $4.2M for 349,203 services; 2024 $4.4M for 340,618 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,160 | 408 | $8.64 | $10K |
| 85025 Blood Count | 1,146 | 402 | $7.60 | $8,715 |
| 80053 Clinical Chemistry | 989 | 354 | $10.34 | $10K |
| 82728 Clinical Chemistry | 219 | 125 | $13.29 | $2,911 |
| 84466 Clinical Chemistry | 191 | 113 | $12.31 | $2,352 |
| 83540 Clinical Chemistry | 191 | 113 | $6.25 | $1,193 |
| 84443 Clinical Chemistry | 186 | 76 | $16.46 | $3,062 |
| 82378 Clinical Chemistry | 177 | 52 | $18.58 | $3,289 |
| 83615 Clinical Chemistry | 169 | 99 | $5.89 | $995 |
| 82607 Clinical Chemistry | 114 | 86 | $14.54 | $1,657 |
Medicare prescription drug claims, 2024
In 2024, the drug Matthew S Weissler prescribed most often to Medicare patients was Anastrozole, with 179 prescriptions and refills. In total Matthew S Weissler wrote 2,009 Medicare prescriptions that cost $6.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 179 | 374 | 39 | $2,578 |
| Omeprazole Generic | 142 | 196 | 43 | $1,007 |
| Eliquis Apixaban | 126 | 141 | 19 | $79K |
| Prednisone Generic | 105 | 110 | 24 | $599 |
| Tamoxifen Citrate Generic | 90 | 168 | 19 | $2,220 |
| Ondansetron Hcl Generic | 88 | 88 | 50 | $4,632 |
| Valacyclovir Valacyclovir Hcl | 78 | 135 | 17 | $2,456 |
| Hydroxyurea Generic | 75 | 106 | 15 | $1,567 |
| Dexamethasone Generic | 74 | 85 | 32 | $1,636 |
| Abiraterone Acetate Generic | 67 | 73 | Under 11 | $40K |
| Exemestane Generic | 55 | 119 | 14 | $7,014 |
| Brukinsa Zanubrutinib | 51 | 51 | Under 11 | $748K |
| Pomalyst Pomalidomide | 39 | 39 | Under 11 | $879K |
| Imbruvica Ibrutinib | 36 | 36 | Under 11 | $558K |
| Letrozole Generic | 35 | 69 | Under 11 | $515 |
Brand drugs: 557 claims; generic drugs: 1,452 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Matthew S Weissler were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.